Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Patients undergoing deep sedation for outpatient procedures typically receive a combination
of benzodiazepines, propofol, and opioids. Side effects of such anesthetics include
respiratory depression, nausea and vomiting, and urinary retention, with resultant extended
hospital stays and unanticipated admission. The use of dexmedetomidine for deep sedation may
increase patient safety by maintaining respiratory drive, while providing sedation, hypnosis,
and analgesia. Furthermore, patients may experience decreased pain, nausea, and time to
discharge in the PACU, especially if dexmedetomidine decreases the requirement of other drugs
such as opioids.
The hypothesis of this study is administration of dexmedetomidine during deep sedation for
ambulatory hysteroscopic surgery will result in a 50% reduction of intraoperative opioid
compared to sedation with propofol.